Viridian Therapeutics (NASDAQ:VRDN) Earns Outperform Rating from Oppenheimer

Oppenheimer restated their outperform rating on shares of Viridian Therapeutics (NASDAQ:VRDN) in a research report report published on Monday, Benzinga reports. The brokerage currently has a $28.00 target price on the stock, down from their prior target price of $31.00.

A number of other equities research analysts also recently commented on VRDN. Wolfe Research initiated coverage on shares of Viridian Therapeutics in a research report on Tuesday, June 11th. They issued an outperform rating and a $29.00 price objective on the stock. The Goldman Sachs Group initiated coverage on shares of Viridian Therapeutics in a research report on Thursday, June 6th. They issued a buy rating and a $23.00 price objective on the stock. HC Wainwright reissued a buy rating and issued a $27.00 price objective on shares of Viridian Therapeutics in a research report on Tuesday, July 16th. Needham & Company LLC reissued a buy rating and issued a $30.00 price objective on shares of Viridian Therapeutics in a research report on Tuesday, June 11th. Finally, B. Riley downgraded shares of Viridian Therapeutics from a buy rating to a neutral rating and dropped their target price for the company from $25.00 to $20.00 in a research report on Thursday, May 9th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, Viridian Therapeutics presently has a consensus rating of Moderate Buy and an average price target of $31.20.

Viridian Therapeutics Price Performance

Shares of VRDN opened at $14.92 on Monday. Viridian Therapeutics has a fifty-two week low of $10.93 and a fifty-two week high of $24.18. The firm’s 50 day moving average price is $13.97 and its 200 day moving average price is $15.47. The company has a market cap of $952.22 million, a P/E ratio of -3.32 and a beta of 1.13. The company has a quick ratio of 23.99, a current ratio of 23.99 and a debt-to-equity ratio of 0.05.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($1.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.15). Viridian Therapeutics had a negative net margin of 79,185.77% and a negative return on equity of 89.20%. The firm had revenue of $0.07 million during the quarter, compared to analysts’ expectations of $0.09 million. On average, research analysts forecast that Viridian Therapeutics will post -3.7 earnings per share for the current fiscal year.

Institutional Trading of Viridian Therapeutics

Large investors have recently bought and sold shares of the business. Ameritas Investment Partners Inc. boosted its stake in Viridian Therapeutics by 19.2% during the 1st quarter. Ameritas Investment Partners Inc. now owns 4,961 shares of the company’s stock worth $87,000 after purchasing an additional 799 shares during the period. Quest Partners LLC lifted its stake in shares of Viridian Therapeutics by 344.0% in the 2nd quarter. Quest Partners LLC now owns 6,056 shares of the company’s stock worth $79,000 after acquiring an additional 4,692 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Viridian Therapeutics by 122.6% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,369 shares of the company’s stock worth $182,000 after acquiring an additional 4,610 shares during the period. Arizona State Retirement System acquired a new stake in shares of Viridian Therapeutics in the 4th quarter worth $208,000. Finally, Principal Financial Group Inc. lifted its stake in shares of Viridian Therapeutics by 9.7% in the 1st quarter. Principal Financial Group Inc. now owns 11,915 shares of the company’s stock worth $209,000 after acquiring an additional 1,058 shares during the period.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.